Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2019-05-22, Stock:PFE, The news for the past five days is as follows:
2019-05-15: NEWS1: Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting.NEWS2: After Hours Most Active for May 15, 2019 :  ARE, NEM, MRC, PFE, SQ, F.NEWS3: After Hours Most Active for May 15, 2019 :  ARE, NEM, MRC, PFE, SQ, F.NEWS4: This Dow Jones Pharma Giant Is Now A &apos;Top Pick&apos; — Here&apos;s Why.NEWS5: Dow Movers: CAT, KO.NEWS6: Dow Movers: CAT, KO.NEWS7: Teva Hits Fibonacci Support on Concerns Over Lawsuit.NEWS8: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS9: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS10: Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer.NEWS11: Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer.NEWS12: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS13: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS14: Pfizer's Bavencio+Inlyta Combo Gets FDA Nod for Kidney Cancer.NEWS15: The Zacks Analyst Blog Highlights: Teva, Mylan, Novartis and Pfizer.NEWS16: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2019.NEWS17: Eli Lilly and Company (LLY) Ex-Dividend Date Scheduled for May 16, 2019.NEWS18: The Daily Biotech Pulse: FDA Greenlights Pfizer-Merck KGAa's Kidney Cancer Combo Treatment, Adcom Disappointment For Daiichi.NEWS19: AbbVie Settles Humira Litigation With Boehringer Ingelheim.NEWS20: Pfizer's atopic dermatitis treatment meets goals in late-stage study.NEWS21: Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates.NEWS22: Pfizer's dermatitis treatment meets main goals of late-stage study.NEWS23: Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis.NEWS24: FDA Approves BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma.
2019-05-16: NEWS1: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS2: XLV, JNJ, UNH, PFE: Large Inflows Detected at ETF.NEWS3: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS4: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS5: Pfizer Gains After Being Named 'Top Pick' by Credit Suisse.NEWS6: Pfizer's Eczema Candidate Meets All Goals in Phase III Study.NEWS7: Here are the biggest analyst calls of the day: Macy&apos;s, Pfizer, Owens Corning & more.NEWS8: Stocks making the biggest moves premarket: Walmart, Pfizer, PG&E, Sony, Tesla & more.NEWS9: Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?.
2019-05-17: NEWS1: After Hours Most Active for May 17, 2019 :  QCOM, VIPS, QQQ, VEON, PFE, WFC, ATI, INTC, WMT, CECO, TEF, IQ.NEWS2: After Hours Most Active for May 17, 2019 :  QCOM, VIPS, QQQ, VEON, PFE, WFC, ATI, INTC, WMT, CECO, TEF, IQ.NEWS3: Health Care Sector Update for 05/17/2019: ACHN, OTLK, MOR, JNJ, PFE, ABT, MRK, AMGN.NEWS4: Health Care Sector Update for 05/17/2019: ACHN, OTLK, MOR, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Pharma Stock Roundup: FDA Okays Line Extensions of LLY, PFE, ABBV Cancer Drugs.NEWS6: Dow 30 Stock Roundup: Walmart, Cisco Earnings Impress.
2019-05-20: NEWS1: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS2: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS3: Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock.NEWS4: Health Care Sector Update for 05/20/2019: MDCO, QGEN, INNT, JNJ, PFE, ABT, MRK, AMGN.NEWS5: Health Care Sector Update for 05/20/2019: MDCO, QGEN, INNT, JNJ, PFE, ABT, MRK, AMGN.
2019-05-21: NEWS1: Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint.NEWS2: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.NEWS3: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.NEWS4: Better Buy: AbbVie vs. Pfizer.NEWS5: Better Buy: AbbVie vs. Pfizer.NEWS6: Better Buy: AbbVie vs. Pfizer.NEWS7: Merck's Keytruda Fails in Late-Stage Breast Cancer Study.

Answer: Rise